Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.
Sana Biotechnology, a US-based stem cell medicines developer exploiting Harvard University research, has filed for a $150m initial public offering on the Nasdaq Global Select Market.
The company had confidentially filed in November 2020 and is yet to set any pricing terms. Morgan Stanley, Goldman Sachs, JP Morgan and BofA Securities have been hired as joint bookrunnning managers.
Founded in 2018, Sana Biotechnology is working on hypoimmune stem cells that are able to hide from the patient’s…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
